Sign in
4

Changes in Ownership

Dianthus Therapeutics, Inc. /DE/ Filed Acc 0001669866-26-000010

CEO AND PRESIDENT sold 166,000 shares at an average $108.11 ($17,945,451)

  • CEO AND PRESIDENT acquired 166,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Garcia Marino · CEO AND PRESIDENT

Table I: Non-derivative

9 lines
Date Transaction Shares Price Value Owned after D/I
2026-08-07 Exercise or conversion : show line 1 in the form 10b5-1 +40,000 $8.44 $337,600 105,292 D
2026-08-07 Exercise or conversion : show line 2 in the form 10b5-1 +126,000 $8.44 $1,063,440 231,292 D
2026-08-07 Sale : show line 3 in the form 10b5-1 −10,384 $107.49 $1,116,176 220,908 D
2026-08-07 Sale : show line 4 in the form 10b5-1 −23,907 $108.05 $2,583,151 197,001 D
2026-08-07 Sale : show line 5 in the form 10b5-1 −2,373 $109.10 $258,894 194,628 D
2026-08-07 Sale : show line 6 in the form 10b5-1 −2,536 $110.02 $279,011 192,092 D
2026-08-07 Sale : show line 7 in the form 10b5-1 −800 $110.76 $88,608 191,292 D
2026-08-07 Sale : show line 8 in the form 10b5-1 −104,091 $107.96 $11,237,664 87,102 D
2026-08-07 Sale : show line 9 in the form 10b5-1 −21,909 $108.72 $2,381,946 65,292 D
Open-market sales · 166,000 sh · avg $108.11 · $17,945,451

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2026-08-07 Exercise or conversion : show line 10 in the form 10b5-1 Stock Option (Right to Buy) −40,000 286,004 D
2026-08-07 Exercise or conversion : show line 11 in the form 10b5-1 Stock Option (Right to Buy) −126,000 160,004 D
Loading xslF345X06/ownership.xml…